Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Betaine anhydrous for oral solution is indicated in children and adults for the treatment of homocystinuria to decrease high homocysteine blood levels. The program will provide prescription fulfillment, insurance benefits investigation, educational suppo...
Brand Name : Cystadane-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 10, 2023
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Cystadane (betaine anhydrous) transfers a methyl group via the enzyme betaine homocysteine methyl transferase, converting homocysteine back into methionine and dimethylglycine. In patients with homocystinuria, betaine reduces homocysteine levels and impr...
Brand Name : Cystadane
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 02, 2023
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Betaine shares the same prescriber base as the carglumic acid tablets, so it is an attractive opportunity to leverage the existing commercial infrastructure.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : Betaine
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : Eton Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
Details : Company’s patented hydrogel-forming microneedle patch, PHARMAPATCH™, to deliver ketamine and KETABET™ (ketamine and betaine anhydrous), which aims to prevent the potential side effects of repeated ketamine treatment for depression and other indicat...
Brand Name : Ketabet
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 29, 2022
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
PharmaTher Announces Positive Results from Study of KETABET for Depression
Details : KETABET (Ketamine and Betaine) aims to prevent the potential adverse psychiatric effects of repeated ketamine treatment for depression and other indications, including suicidal ideation, substance abuse, post-traumatic stress disorder, and chronic pain.
Brand Name : Ketabet
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 07, 2022
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Patent granted strengthen the Company’s global patent portfolio and it provides for broad potential of KETABET™(Ketamine) for uses in various mental health, neurological and pain disorders, as well as novel delivery forms.
Brand Name : Ketabet MN
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 30, 2021
Lead Product(s) : Ketamine Hydrochloride,Betaine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?